SCHEMBL24257830

SCHEMBL24257830

Cc1c(-c2cnc(-c3ccccc3)o2)cnc(C#N)c1OCc1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 9/20 0.43
KDM4E B2RXH2 8/20 0.43
ALDH1A1 P00352 8/20 0.43
HPGD P15428 8/20 0.43
MAPT P10636 6/20 0.43
KMT2A Q03164 4/20 0.43
MEN1 O00255 3/20 0.43
HTT P42858 2/20 0.43
RAB9A P51151 2/20 0.43
LMNA P02545 1/20 0.43
POLB P06746 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
TSHR P16473 2/20 0.41
ALOX15 P16050 1/20 0.41
CASP1 P29466 1/20 0.41
PTPN1 P18031 2/20 0.39
GAA P10253 4/20 0.39
MAPK1 P28482 4/20 0.39
BRD4 O60885 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24257561 0.80 RAB9A (0.41) HSD17B10KDM4EALDH1A1HPGDMAPT
SCHEMBL24257813 0.79 ALOX15 (0.47) HSD17B10KDM4EALDH1A1HPGDMAPT
SCHEMBL30453166 0.79 CYP11B1 (0.47) HSD17B10KDM4EALDH1A1HPGDMAPT
SCHEMBL24257578 0.79 CYP11B1 (0.47) HSD17B10KDM4EALDH1A1HPGDMAPT
SCHEMBL24257768 0.79 SQOR (0.42) HSD17B10KDM4EALDH1A1HPGDMAPT
SCHEMBL30546888 0.78 CYP11B1 (0.42) HSD17B10KDM4EALDH1A1HPGDMAPT
SCHEMBL24257687 0.78 CYP11B1 (0.42) HSD17B10KDM4EALDH1A1HPGDMAPT
SCHEMBL24257777 0.77 MAPT (0.42) HSD17B10KDM4EALDH1A1HPGDMAPT
SCHEMBL24257769 0.77 C5AR1 (0.41) HSD17B10KDM4EALDH1A1HPGDMAPT
SCHEMBL24257771 0.77 GRM5 (0.42) KDM4EHPGDMAPTPOLBMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
WO-2022036188-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE HIF1AN, EGLN3, PHF20 HSD17B10 912/4885KDM4E 175/4885ALDH1A1 1362/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.